We recently examined the reproducibility of MYC and BCL-2 immunohistochemical (IHC) scoring and the impact of high expression of MYC and BCL-2 (double expresser status, DE) on survival and progression in a large retrospective cohort of aggressive B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or R-CHOP-like regimens. We found that IHC scoring for MYC and BCL-2 was highly reproducible when cut-off values of ≥70% for MYC and ≥50% for BCL-2 were used. This threshold also predicted the presence of gene rearrangements identifying MYC translocations in 88% of cases. Patients with dual MYC expression of ≥70% and BCL-2 expression of ≥50% showed a significantly inferior clinical course and, therefore, represent candidates for novel treatment modalities. We have now validated these findings in an independent cohort of 461 patients enrolled in prospective clinical trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients / Ziepert, Marita; Lazzi, Stefano; Santi, Raffaella; Vergoni, Federica; Granai, Massimo; Mancini, Virginia; Staiger, Annette; Horn, Heike; Löffler, Markus; Pöschel, Viola; Held, Gerhald; Wulf, Gerald; Trümper, Lorenz H; Schmitz, Norbert; Rosenwald, Andreas; Sabattini, Elena; Naresh, Kikkeri N; Stein, Harald; Ott, German; Leoncini, Lorenzo. - In: HAEMATOLOGICA. - ISSN 0390-6078. - STAMPA. - 105:(2020), pp. 2667-2670. [10.3324/haematol.2019.235556]

A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients

Santi, Raffaella;
2020

Abstract

We recently examined the reproducibility of MYC and BCL-2 immunohistochemical (IHC) scoring and the impact of high expression of MYC and BCL-2 (double expresser status, DE) on survival and progression in a large retrospective cohort of aggressive B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or R-CHOP-like regimens. We found that IHC scoring for MYC and BCL-2 was highly reproducible when cut-off values of ≥70% for MYC and ≥50% for BCL-2 were used. This threshold also predicted the presence of gene rearrangements identifying MYC translocations in 88% of cases. Patients with dual MYC expression of ≥70% and BCL-2 expression of ≥50% showed a significantly inferior clinical course and, therefore, represent candidates for novel treatment modalities. We have now validated these findings in an independent cohort of 461 patients enrolled in prospective clinical trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
2020
105
2667
2670
Ziepert, Marita; Lazzi, Stefano; Santi, Raffaella; Vergoni, Federica; Granai, Massimo; Mancini, Virginia; Staiger, Annette; Horn, Heike; Löffler, Markus; Pöschel, Viola; Held, Gerhald; Wulf, Gerald; Trümper, Lorenz H; Schmitz, Norbert; Rosenwald, Andreas; Sabattini, Elena; Naresh, Kikkeri N; Stein, Harald; Ott, German; Leoncini, Lorenzo
File in questo prodotto:
File Dimensione Formato  
9647-Article Text-71179-2-10-20201021.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 1.41 MB
Formato Adobe PDF
1.41 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1300471
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 18
social impact